Contact Us
Drug Search Results
More Filters [+]

AZD1480

Alternative Names: azd1480
Latest Update: 2023-11-11
Latest Update Note: PubMed Publication

Product Description

AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2).  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23847256/)

Mechanisms of Action: JAK2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD1480

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Myelofibrosis|Myeloproliferative Disorders

Phase 1: Thrombocytosis|Polycythemia Vera|Myeloproliferative Disorders|Thrombocythemia, Essential|Myelofibrosis|Gastrointestinal Cancer|Small Cell Lung Cancer|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2007-006647-45

P2

Completed

Myelofibrosis|Myeloproliferative Disorders

2014-08-25

D1060C00004

P1

Terminated

Small Cell Lung Cancer|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer

2012-12-01

D1060C00002

P1

Terminated

Non-Small-Cell Lung Cancer

2012-09-01

D1060C00001

P1

Completed

Thrombocythemia, Essential|Polycythemia Vera|Myelofibrosis|Thrombocytosis|Myeloproliferative Disorders

2012-03-01

Recent News Events

Date

Type

Title

11/11/2023

PubMed

 LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy.

11/01/2023

PubMed

 High-dose radiation-resistant lung cancer cells stored many functional lipid drops through JAK2/p-STAT3/FASN pathway.

10/18/2023

PubMed

 M1 macrophage-derived oncostatin M induces osteogenic differentiation of ligamentum flavum cells through the JAK2/STAT3 pathway.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions